Robert J. Padley

5.3k total citations · 3 hit papers
65 papers, 3.9k citations indexed

About

Robert J. Padley is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Robert J. Padley has authored 65 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Physiology and 15 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robert J. Padley's work include Nitric Oxide and Endothelin Effects (16 papers), Hormonal and reproductive studies (12 papers) and Heart Failure Treatment and Management (9 papers). Robert J. Padley is often cited by papers focused on Nitric Oxide and Endothelin Effects (16 papers), Hormonal and reproductive studies (12 papers) and Heart Failure Treatment and Management (9 papers). Robert J. Padley collaborates with scholars based in United States, United Kingdom and Germany. Robert J. Padley's co-authors include Roopal Thakkar, Milton Packer, Markku S. Nieminen, Alexandre Mebazaa, Alain Cohen‐Solal, Matti Kivikko, Stuart Pocock, Franz X. Kleber, William O. Williford and Herbert Lepor and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Robert J. Padley

65 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure

2007 645 citations Alexandre Mebazaa, Markku S. Nieminen et al. profile →
The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

1996 594 citations Herbert Lepor, William O. Williford et al. New England Journal of Medicine profile →
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

2018 276 citations Julie Parmentier, J W Voss et al. BMC Rheumatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Padley United States	24	1.3k	1.2k	811	610	581	65	3.9k
Akira Miyajima Japan	37	443 0.3×	1.6k 1.3×	502 0.6×	261 0.4×	1.7k 2.9×	274	5.1k
Shigeto Ishidoya Japan	25	249 0.2×	796 0.7×	284 0.4×	195 0.3×	752 1.3×	111	2.2k
Kentaro Yamashita Japan	30	422 0.3×	581 0.5×	47 0.1×	191 0.3×	805 1.4×	153	3.5k
Barry S. Oemar Switzerland	25	787 0.6×	781 0.7×	67 0.1×	206 0.3×	424 0.7×	51	3.8k
Hirotoshi Morii Japan	37	856 0.7×	730 0.6×	25 0.0×	639 1.0×	847 1.5×	169	5.8k
Tobias Geisler Germany	39	3.2k 2.5×	381 0.3×	47 0.1×	128 0.2×	1.5k 2.6×	233	5.8k
Gustav Fraedrich Austria	36	3.0k 2.4×	4.8k 4.1×	65 0.1×	381 0.6×	1.7k 2.9×	164	6.2k
Toshikazu Tanaka Japan	22	497 0.4×	396 0.3×	84 0.1×	64 0.1×	524 0.9×	131	1.9k
Vandana Sachdev United States	34	951 0.8×	750 0.6×	28 0.0×	214 0.4×	335 0.6×	107	4.6k
Barbara A. Thornhill United States	28	253 0.2×	781 0.7×	400 0.5×	86 0.1×	323 0.6×	66	2.9k

Countries citing papers authored by Robert J. Padley

Since Specialization

Citations

This map shows the geographic impact of Robert J. Padley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Padley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Padley more than expected).

Fields of papers citing papers by Robert J. Padley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Padley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Padley. The network helps show where Robert J. Padley may publish in the future.

Co-authorship network of co-authors of Robert J. Padley

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Padley. A scholar is included among the top collaborators of Robert J. Padley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Padley. Robert J. Padley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Parmentier, Julie, J W Voss, Candace Graff, et al.. (2018). In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology. 2(1). 23–23. 276 indexed citations breakdown →

2.

Mohamed, Mohamed‐Eslam F., Heidi S. Camp, Ping Jiang, et al.. (2016). Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clinical Pharmacokinetics. 55(12). 1547–1558. 101 indexed citations

3.

Packer, Milton, Wilson S. Colucci, Lloyd D. Fisher, et al.. (2013). Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. JACC Heart Failure. 1(2). 103–111. 285 indexed citations

4.

Böhm, Michael, Andreas Link, Markku S. Nieminen, et al.. (2011). Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial*. Critical Care Medicine. 39(5). 940–944. 43 indexed citations

5.

Tóth, Peter P., William Insull, Robert J. Padley, et al.. (2010). Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vascular Health and Risk Management. 6. 1065–1065. 9 indexed citations

6.

Mebazaa, Alexandre, Markku S. Nieminen, Gerasimos Filippatos, et al.. (2009). Levosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVE. European Journal of Heart Failure. 11(3). 304–311. 117 indexed citations

7.

Kawata, Ariane K., Dennis A. Revicki, Roopal Thakkar, et al.. (2009). Flushing ASsessment Tool (FAST©). Clinical Drug Investigation. 29(4). 215–229. 18 indexed citations

8.

Insull, William, Jan Basile, Anthony Vo, et al.. (2009). Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. Journal of clinical lipidology. 3(2). 109–118. 23 indexed citations

9.

Thakkar, Roopal, Moti L. Kashyap, Andrew Lewin, et al.. (2009). Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia. American Journal of Cardiovascular Drugs. 9(2). 69–79. 18 indexed citations

10.

Mohammad, Khalid S., et al.. (2001). Endothelin-1 (ET-1) mediates pathological but not normal bone remodeling. Breast Cancer Research and Treatment. 69(3). 2 indexed citations

11.

Samara, Emil, Sandeep Dutta, Guoliang Cao, et al.. (2001). Single‐Dose Pharmacokinetics of Atrasentan, an Endothelin‐A Receptor Antagonist. The Journal of Clinical Pharmacology. 41(4). 397–403. 21 indexed citations

12.

Tolcher, Anthony W., Ann R. Kennedy, Robert J. Padley, et al.. (2001). Other novel agents: Rationale and current status as chemopreventive agents. Urology. 57(4). 86–89. 16 indexed citations

13.

Padley, Robert J., et al.. (2001). Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma. Biomedical Chromatography. 15(8). 525–533. 9 indexed citations

14.

Jarvis, Michael F., Jerry L. Wessale, Chang Zhu, et al.. (2000). ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. European Journal of Pharmacology. 388(1). 29–35. 91 indexed citations

15.

Opgenorth, Terry J., Jerry L. Wessale, Douglas B. Dixon, et al.. (2000). Effects of Endothelin Receptor Antagonists on the Plasma Immunoreactive Endothelin-1 Level. Journal of Cardiovascular Pharmacology. 36(Supplement 1). S292–S296. 28 indexed citations

16.

Honing, Marina L. H., et al.. (2000). Selective ETA Receptor Antagonism with ABT-627 Attenuates All Renal Effects of Endothelin in Humans. Journal of the American Society of Nephrology. 11(8). 1498–1504. 37 indexed citations

17.

Opgenorth, Terry J., Jerry L. Wessale, Douglas B. Dixon, et al.. (2000). Effects of Endothelin Receptor Antagonists on the Plasma Immunoreactive Endothelin-1 Level. Journal of Cardiovascular Pharmacology. 36. S292–S296. 5 indexed citations

18.

Roehrborn, Claus G., Joseph E. Oesterling, Stephen M. Auerbach, et al.. (1996). The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology. 47(2). 159–168. 175 indexed citations

19.

Lepor, Herbert, William O. Williford, Michael J. Barry, et al.. (1996). The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia. New England Journal of Medicine. 335(8). 533–540. 594 indexed citations breakdown →

20.

Hillman, Alan L., J. Sanford Schwartz, Mary Kaye Willian, et al.. (1996). The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology. 47(2). 169–178. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact